Publications

Original Research and Commentary on p28 CDG Therapeutics Lead Agent and Analogs

Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.

Signorelli S, Santini S, Yamada T, Bizzarri AR, Beattie CW, Cannistraro S.

Biochim Biophys Acta. 2017 Apr;1861(4):910-921.

 

Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Lulla RR, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M.

Neuro Oncol., 2016 Sep;18(9):1319-25

 

p28-mediated Activation of p53 in G2/M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.

Yamada T, Das Gupta TK, Beattie CW.

Cancer Res. 2016 Feb 26; 76(8): 2354-2365

 

Chirality Switching within an Anionic Cell-Penetrating Peptide Inhibits Translocation without Affecting Preferential Entry.

Yamada T, Signorelli S, Cannistraro S, Beattie CW, Bizzarri AR.

Mol Pharm. 2015 Jan 5;12(1):140-9. doi: 10.1021/mp500495u. Epub 2014 Dec 5.

 

A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.

Coppari E, Yamada T, Bizzarri AR, Beattie CW, Cannistraro S.

Int J Nanomedicine. 2014 Apr 10;9:1799-813. doi: 10.2147/IJN.S58465. eCollection 2014.

 

p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.

Yamada T, Das Gupta TK, Beattie CW.

Mol Pharm. 2013 Sep 3;10(9):3375-83. doi: 10.1021/mp400221r. Epub 2013 Aug 16.

 

Targeted therapies: One step closer to drugging p53.

Razzak M.

Nat Rev Clin Oncol. 2013 May;10(5):246. doi: 10.1038/nrclinonc.2013.43. Epub 2013

 

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, Das Gupta TK.

Br J Cancer. 2013 Mar 19;108(5):1061-70. doi: 10.1038/bjc.2013.74. Epub 2013 Feb 28.

 

p28, a first in class peptide inhibitor of cop1 binding to p53.

Yamada T, Christov K, Shilkaitis A, Bratescu L, Green A, Santini S, Bizzarri AR, Cannistraro S, Gupta TK, Beattie CW.

Br J Cancer. 2013 Jun 25;108(12):2495-504. doi: 10.1038/bjc.2013.266. Epub 2013 Jun 4.

 

Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.

Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S. Int J Nanomedicine. 2011;6:3011-9. doi: 10.2147/IJN.S26155. Epub 2011 Nov 24.

 

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.

Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, Green A, Beattie CW, Das Gupta TK.

Angiogenesis. 2011 Sep;14(3):355-69. doi: 10.1007/s10456-011-9220-6. Epub 2011 Jun 11.

 

A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L.

J Pharm Biomed Anal. 2010 Dec 1;53(4):991-6. doi: 10.1016/j.jpba.2010.06.006. Epub 2010 Jun 30.

 

A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.

Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK.

Cancer Prev Res (Phila). 2010 Oct;3(10):1351-60. doi: 10.1158/1940-6207.CAPR-10-0024. Epub 2010 Sep 14.

 

A new class of anticancer peptides isolated from azurin.

Yamada T, Beattie CW, Das Gupta TK. chimica Oggi / CHEMISTRY to day, Oligos & Peptides 2010 January/February; 28(1)

 

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3. Epub 2010 Nov 18.

 

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.

Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK.

Mol Cancer Ther. 2009 Oct;8(10):2947-58. doi: 10.1158/1535-7163.MCT-09-0444. Epub 2009 Oct 6.

 

Noncationic peptides obtained from azurin preferentially enter cancer cells.

Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Das Gupta TK.

Cancer Res. 2009 Jan 15;69(2):537-46. doi: 10.1158/0008-5472.CAN-08-2932.